The digital medicine provider has closed a round led by SoftBank Vision Fund 2 that also featured Novartis, taking its total funding to at least $214m.

Telecommunications and internet group SoftBank’s Vision Fund 2 led an $80m series D round for US-based digital therapeutics product developer Pear Therapeutics on Tuesday.

Pharmaceutical firm Novartis also took part in the round, along with Temasek, 5AM Ventures, Arboretum Ventures, Jazz Venture Partners, EDBI, Forth Management, Pilot House, Sarissa Capital, Shanda Group, CrimsoNox and Quad Investment Management.

Pear is developing a portfolio of prescription digital therapeutics to treat diseases, either by themselves or in tandem with drug treatments. It has…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn